BARDA Hails FDA's Approval of Flu Vaccine Manufacturing

The first approval to manufacture seasonal influenza vaccine using cell-based technology in a U.S. facility "demonstrates the effectiveness of a multi-use approach to emergency preparedness," Director Robin Robinson, Ph.D., noted June 17.

Calling it a milestone event in the nation's readiness to combat seasonal or pandemic influenza, Biomedical Advanced Research and Development Authority (BARDA) Director and Deputy Assistant Secretary for Preparedness and Response Robin Robinson, Ph.D., praised the U.S. Food and Drug Administration's first approval for manufacturing seasonal influenza vaccine using cell-based technology in a U.S. facility. The facility is owned by Novartis of Basel, Switzerland, and located in Holly Springs, N.C., and the approval means it can manufacture cell-based vaccine against seasonal and pandemic influenza viruses. "This new capability demonstrates the effectiveness of a multi-use approach to emergency preparedness," Robinson wrote.

BARDA sponsors the development of new technologies for use in emergencies, including the cell-based technology used at Holly Springs. The facility was built through a partnership established in 2009 between BARDA and Novartis to increase the domestic production capacity of pandemic flu vaccine and quickly provide additional influenza vaccines to combat public health threats.

According to BARDA, the Holly Springs facility can produce up to 200 million doses of pandemic influenza vaccine within six months of the declaration of a pandemic.

Download Center

HTML - No Current Item Deck
  • Green Quadrant EHS Software 2021

    Reserve your copy of the new report by independent analyst firm, Verdantix, to get a detailed, fact-based comparison of the 22 most prominent EHS software vendors in the industry.

  • Best Practices to Navigate ISO 45001

    Learn helpful tips and tricks to navigate your transition to ISO 45001 certification and ensure an effective health and safety management system.

  • Improve Your Safety Culture

    Learn the 3 fundamental areas to focus on to achieve safety culture excellence and what you can do to boost employee engagement in your EHS programs.

  • Chemical Safety: 5 Questions Answered by Experts

    Get answers to 5 of the most frequently asked questions about how to effectively mitigate chemical risk, get the most value out of your chemical data, and gain buy-in for a chemical management technology program.

  • How Has COVID-19 Changed Safety Culture?

    The COVID-19 pandemic has provided unique opportunities for health and safety professionals to rethink how they manage risk and develop stronger safety cultures. Read this eBook to learn actionable steps you can implement today to improve your programs.

  • Industry Safe

OH&S Digital Edition

  • OHS Magazine Digital Edition - January February 2021

    January February 2021

    Featuring:

    • TRAINING: SOFTWARE
      Tips for Choosing the Best Training Software
    • COMBUSTIBLE DUST
      Assessing the Dangers of Dust Explosions
    • HAND PROTECTION
      Pushing the Boundaries of Hand Protection
    • FOOT PROTECTION
      Getting a Grip on Slip Resistance
    View This Issue